Rauwolfia use and breast cancer: a case-control study

Area of Science:

• Epidemiology
• Oncology
• Pharmacology

Background:

• Hypertension is a common condition often treated with various medications.
• Previous studies have explored potential links between antihypertensive drugs and breast cancer risk, with mixed results.
• Rauwolfia derivatives are a class of antihypertensive medications with a history of use.

Purpose of the Study:

• To investigate the association between hypertension, antihypertensive medication use, and breast cancer risk.
• To specifically examine the risk related to rauwolfia derivatives, thiazide preparations, and methyldopa.
• To determine if duration and timing of rauwolfia use influence breast cancer risk.

Main Methods:

• A case-control study involving 1,362 breast cancer cases and 1,250 controls.
• Participants were part of a large multicenter screening program.
• Data collected included history of hypertension and use of specific antihypertensive medications.

Main Results:

• No increased breast cancer risk was found for hypertension itself or for short-term use of rauwolfia derivatives, thiazides, or methyldopa.
• A significantly elevated risk of breast cancer was observed among long-term users of rauwolfia derivatives (≥10 years duration).
• Women whose initial rauwolfia use began 10 or more years prior to diagnosis also showed increased risk.

Conclusions:

• Long-term exposure to rauwolfia derivatives is associated with an elevated risk of breast cancer.
• Hypertension and shorter-term use of antihypertensives do not appear to increase breast cancer risk.
• These findings highlight the importance of considering medication history, particularly duration of use, in breast cancer risk assessment.